AIP
REGN icon

Almanack Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Almanack Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$201K – 161
2016
Q4 		$201K Buy
+1,000
New +$380K 0.17% 66

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Almanack Investment Partners's REGN Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 649 shares worth $405K. The stake represents 0.05% of the portfolio and ranks #189 among its holdings. This is a return to the name: Almanack Investment Partners previously reported a position in REGN as recently as Q2 2024.

Almanack Investment Partners first reported a position in REGN in Q4 2022 and has held it in 8 quarters since. The position peaked at $8.15M in Q4 2022. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Almanack Investment Partners held 649 shares of Regeneron Pharmaceuticals worth $405K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Almanack Investment Partners position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.05% of Almanack Investment Partners's portfolio in Q2 2026, its #189 holding.
  • Almanack Investment Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • Almanack Investment Partners's Regeneron Pharmaceuticals position peaked at $8.15M in Q4 2022.
  • 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.